Pharmaceuticals
This Portfolio of 2021 Losers Is Struggling to Gain Ground in 2022
A few disappointing earnings reports are dragging down a handful of the stocks that make up the 2022 Tax Loss Selling Recovery Portfolio.
A Clear Look and Play on a Low-Priced Ocular Name
Option premiums are solid, and liquidity is good, making this $5 stock an effective covered call candidate.
This Stock Has Had Good 2-Year Run -- But That May Be About to Change
You might not immediately think of this name as a big winner over the last two years.
Walgreens Gets Booted Down a Notch: How We'd Play It
The fundamentals and the charts are on the same page.
Put a HALO Over Your Portfolio With My Top Pick for the Second Quarter
The charts of this biotech name are setting up impressively right now.
Telsa, Regeneron and Global Foundries: How I'd Approach Each Stock Right Now
The EV maker looks ripe for a dip, while the pharmaceutical giant and chip producer could make for swing trades.
Bausch Health's Charts Continue to Look Out of Focus
The technical signals of the diversified health care company still don't inspire confidence to establish long positions in its stock at this time.
Let's Put the IQ Healthy Hearts ETF Through Its Paces
A closer look at the fund's composition leads to a few head-scratchers, but most of the names seem to fairly represent its focus.
Could Fresh Global Outbreaks Move the Needle for Moderna?
As several parts of the world struggle with Covid-19 surges, MRNA could win in the long war against the pandemic.
Invest in AbbVie? I've Made My Decision
The dividend in ABBV is key to making any investment decision regarding the stock.